Omeros Corporation announced that it has requested Fast Track Designation from the FDA for the development of OMS824 for the treatment of Huntington’s disease. OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an enzyme found in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington’s disease and schizophrenia.
OMS824 is being developed for the treatment of cognitive disorders. In addition to possible benefits on cognition, it may also improve psychiatric manifestations, such as positive (eg, hallucinations) and negative (eg, flat effect) symptoms of schizophrenia.
Omeros is currently advancing OMS824 into a Phase 2 program.
For more information call (206) 676-5000 or visit www.omeros.com.